Drug Trial Radar · NCT06973564
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
344
Planned (sponsor's estimate)
Start
May 29, 2025
Primary completion
Nov 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
Conditions
- Advanced Solid Tumors
Interventions
JAB-23E73Drug
Oral administration
CetuximabDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number and proportion of patients who experience at least 1 dose-limiting toxicity (DLT) with treatment of JAB-23E73 monotherapy.Time frame: Up to 1 year
- Part A: Safety and tolerability of JAB-23E73 monotherapyTime frame: Up to 2 years
- Part A: Objective response rate (ORR) of JAB-23E73 monotherapy.Time frame: Up to 3 years
- Part B1: Safety, tolerability and RP2D of JAB-23E73 in combination with cetuximab.Time frame: Up to 2 years
- Part B1: Objective response rate (ORR) of JAB-23E73 in combination with cetuximab.Time frame: Up to 3 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.